Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemia

An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication

Bone Marrow Transplantation volume 52, pages 363–371 (2017)Cite this article

Subjects

Abstract

The refined disease risk index (DRI) is a powerful prognostic model based solely on the disease type and stage for predicting survival outcomes of various hematological malignancies after allogeneic transplant. Here, we analyzed our series of 690 patients transplanted over the past 15 years, and showed that besides overall survival (OS), the refined DRI is also able to segregate event-free survival and relapse mortality in our cohort of largely Southeast Asian patients with a long and complete follow-up. Stratification by refined DRI remains statistically significant even when broken down by specific diseases each with a smaller number of patients, as well as for a small subset of patients younger than 18 years old, providing a robust model for prognostication. Multivariable analysis shows that refined DRI, age, year of transplant and donor type are independent risk factors for OS. We further demonstrated here that prognostication for a given patient with a specific disease can be made more discriminating by integrating independent risk factors such as age and donor type with the refined DRI. The future development of prognostic system incorporating the refined DRI with patient- and transplant-related risk factors will provide a more precise estimate of transplant outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

  2. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014; 32: 3249–3256.

    Article  Google Scholar 

  3. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715–4726.

    Article  Google Scholar 

  4. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120: 905–913.

    Article  CAS  Google Scholar 

  5. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123: 3664–3671.

    Article  CAS  Google Scholar 

  6. European Group for Blood and Marrow Transplantation. Definitions and evaluation of endpoints following stem cells transplantation - recommendation from the European Group for Blood and Marrow transplantation (EBMT). Available at https://portal.ebmt.org/sites/clint2/clint/Documents/Statistical%20Endpoints_CLINT%20Project_final%20version.pdf. Accessed on 19 June 2016.

  7. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  Google Scholar 

  8. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.

    Article  CAS  Google Scholar 

  9. Beauverd Y, Roosnek E, Tirefort Y, Nagy-Hulliger M, Bernimoulin M, Tsopra O et al. Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion. Biol Blood Marrow Transplant 2014; 20: 1322–1328.

    Article  Google Scholar 

  10. Lim AB, Roberts AW, Mason K, Bajel A, Szer J, Ritchie DS et al. Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important. Transplantation 2015; 99: 128–132.

    Article  CAS  Google Scholar 

  11. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024–3031.

    Article  CAS  Google Scholar 

  12. Lupo-Stanghellini MR, Sala E, Piemontese S, Morelli M, Greco R, Marcatti M et al. Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) predict survival after haploidentical stem cell transplantation: a comparative study with EBMT risk score in 220 consecutive patients. Blood 2015; 126: 4400.

  13. Aoki J, Yamamoto E, Fujii E, Tanaka M, Kanamori H . Validation of the Refined Disease Risk Index in Patients Receiving Allogeneic Stem Cell Transplantation at a Single Center in Japan. Biol Blood Marrow Transplant 2016; 22: S302–S303.

    Article  Google Scholar 

Download references

Acknowledgements

VVM thanks the Singapore General Hospital Post Graduate Medical Institute for funding and the MS Ramaiah Medical college for clinical fellowship attachment in the Department of Haematology at the Singapore General Hospital.

Author information

Author notes

  1. V V Maka and L-P Koh: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, MS Ramaiah Memorial Hospital, Bangalore, India

    V V Maka

  2. Department of Haematology, Singapore General Hospital, Singapore, Singapore

    V V Maka, C Diong, Y-T Goh, S Gopalakrishnan, A Ho, W Hwang, M Koh, F Lim, Y Loh, P Tan & Y-C Linn

  3. Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore

    L-P Koh, Z-Y Lim, M Poon, D R Del Rosario & L-K Tan

  4. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

    B-C Tai

Authors
  1. V V Maka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L-P Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Diong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-T Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Gopalakrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Z-Y Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y Loh
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Poon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D R Del Rosario
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. B-C Tai
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. L-K Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. P Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Y-C Linn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y-C Linn.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maka, V., Koh, LP., Diong, C. et al. An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. Bone Marrow Transplant 52, 363–371 (2017). https://doi.org/10.1038/bmt.2016.286

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.286

Search

Advanced search

Quick links